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Current trends in type 1 diabetes mellitus - stem cells and beyond
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Abstract
Search for a cure for type-1 diabetes mellitus has
lead to many avenues of research, all having the same
objective: to replace the lost beta cells and prevent their
further destruction by the immune system. Transplantation
of islets of Langerhans seems closer to achieving this goal
with the recent introduction of new improved
immunosuppressive protocols including monoclonal
antibodies against the T-lymphocytes. But the need for
acquiring beta cells in large numbers rather limits this
approach. With the recent advancement in stem cell
technology, it may be possible to gather enough stem cells
for transplantation purposes. In this regard, embryonic stem
cells have shown the greatest promise due to their capacity
for unlimited proliferation and differentiation into any cell
type. This review discusses the current direction of research
regarding diabetes mellitus type-1, while explaining the
progress being made in stem cell usage in finding a cure for
the disease. 
Introduction
Diabetes Mellitius is a clinical syndrome
characterized by hyperglycemia due to absolute or relative
deficiency of insulin. The prevalence of diabetes mellitus is
increasing all over the world and at the present pace of
increase it is anticipated that by the Year 2030 the world will
have over 366 million diabetics.1 Late diabetic
complications will cause considerable morbidity in 5-10%
of these patients and place an enormous burden on the
society. Identifying methods to treat or cure the disease,
along with efforts to prevent its development, will be a key
in stemming this pandemic as both patients and society have
much to gain from development of improved treatment
protocols for diabetes.
Type-1 (insulin-dependent) diabetes is a chronic
disease affecting genetically predisposed individuals, in
which insulin-secreting ß-cells within pancreatic islets of
Langerhans are selectively and irreversibly destroyed by
autoimmune assault. In the treatment of this condition
insulin from exogenous sources has to be given resulting in
strict adherence to dietary rules as well as sometimes
causing erratic glycaemic behavioru. Attempts have been
made to restore normal or near normal metabolic control by
various means. These include islet transplantation2, insulin
gene therapy3 and beta cell regeneration.4 Much progress
has been made in islet isolation technology and less toxic
immunosuppressive therapy but the problem lies in
obtaining sufficiently large numbers of purified islet cells
from cadaveric donors. Insulin gene therapy focuses on
converting non-beta cells into insulin producing cells by
way of introducing insulin synthetic and secretory
techniques. This in a way avoids the body's immune system
but there is no way as yet to control the insulin secretion in
response to a glycemic load. Regeneration of pancreatic
beta cells is now possible given the recent advancements in
stem cell technology. The obvious advantage of using stem
cells is that they can self-replicate and differentiate into any
cell type including the insulin producing beta cells and 
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therefore can be used to treat diabetes mellitus.
Review
Current therapeutic options for Type 1 diabetes
mellitus: For the past 80 years the treatment of type 1
diabetes mellitus had been confined to the use of Insulin
injectable or the recently introduced inhaled form5 the latter
still under consideration. Even with thrice daily insulin
injection along with daily blood glucose monitoring, normal
glycaemic control cannot be achieved.6 Ideally a system
should be devised to sense the blood glucose concentration
and intelligently administer the required amount of insulin
when needed. This can be achieved by an implantable,
glucose-sensing insulin delivery system. Because of the
recent advances made in computer technology, in particular
miniaturization of computer chips and insulin pumps, it may
be possible in future, to develop an implantable computer
driven, "closed loop" insulin delivery system.7
Pancreatic transplantation is another option but the
patient has to take immunosuppressive therapy that have
their own side effects. Therefore, whole pancreatic
transplantation is now attempted usually in cases where
renal transplantation is also being done.8 The latest trend in
the treatment of diabetes mellitus type 1 has been the
transplantation of islets of Langerhans only. The procedure
involves injecting islets into the portal vein. To prevent
rejection of islets, steroid immunosuppression is used, but
this leads to a much higher need for insulin to control the
hyperglycaemia and success is had in only a few percent of
the cases. Recently James Shapiro9 and his colleagues in
Edmonton, Alberta, Canada, developed a protocol, now
called the Edmonton protocol, using larger amount of islet
cells and a different immunosuppression method. This lead
to success in the majority of cases initially but a five year
follow up showed only 10% maintaining insulin
independence.10,11 Much work needs to be done in refining
this protocol as it can become in the near future, a cure for
type 1 diabetes mellitus. One of the major problem with this
approach is finding enough donors as the procedure requires
2 to 4 cadaveric donors. A further modification to islet
transplantation is microencapsulation of human islet
allograft and injecting them intra-peritoneally. It is a simpler
procedure and has yielded good results.12 An alternate
source of islets could be xenografts but this has been
associated with the complications of hyperacute graft
rejection. With new improved immunosuppressive
regimens and the development of genetically engineered
animals this risk has been reduced, however, the possiblity
of transmitting unknown zoonotic infections to the host
recipient remains.13
Another source could be the conversion of  non-beta
cells into insulin producing beta cells by way of
manipulating with the genetic makeup of the cell. Sapir et
al14 by transducing hepatocytes with a single gene, were
able to influence them to transdifferentiate into human beta
cells. The gene under study was the pancreatic and duodenal
homeobox gene-1 (Pdx-1).15 Several researchers have now
shown that this gene is a transcription factor required for the
normal beta cell development.16 As human hepatocytes
were used for the study the question of graft rejection due to
allograft or xenograft did not arise. Also liver cells due to
their inherent quality are easily cultivated in vitro and able
to proliferate rapidly into large enough numbers to be
transplanted as insulin producing islet cells in patients with
type 1 diabetes mellitus.17 Similar experiments have been
done utilizing human bone marrow derived mesenchymal
stem cells. After first infecting them with PDX-1, using
recombinant adenovirus as a vector, these cells were
successfully stimulated to produce insulin.18
Stem Cells
What are stem cells? "Stem cells" is a term used to
describe precursor or unspecialized cells that can give rise
to multiple tissue types. These cells have two important
characteristics. They have the ability to renew themselves
for long periods without differentiating into specialized
cells. And they can, when given the proper signals,
differentiate into cells representative of all three body
lineages: ectoderm, mesoderm, and endoderm. There are
many potential sources for stem cells. Embryonic stem cells
are derived from very early stage of the embryo, the
blastocyst stage.19 Embryonic germ cells are collected from
foetal tissue at a somewhat later stage of development (from
a region called the gonadal ridge), and the cell types that
they can develop into may be slightly limited. Still later,
stem cells can be found in many adult tissues, the adult stem
cells, functioning as a continuing source of mature cells for
that particular region.
Potential sources of stem cells
Human embryonic stem cells: Stem cells represent
a renewable alternative source of insulin-producing cells.
Pluripotent human embryonic stem cells have the potential
to proliferate indefinitely in culture20 and have the ability to
differentiate into any cell type of the body including beta
cells thus providing a cure for diabetes type 1. Removal of
cells from the feeder layer and growing them in suspension
leads to the formation of embryoid bodies.21 These are
clumps of embryonic stem cells consisting of cells from all
the three germ layers. Researchers have found out that
subjecting the embryoid bodies to various growth factors,
including nerve growth factor, leads to their expression of
certain genes such as Pdx-1 which is found expressed
throughout the epithelium of early pancreatic buds and
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plays a role in the development of pancreas.16,22 These
genes can be regarded as cell markers helpful in identifying
the insulin secreting cells. 
Ethical issues are involved regarding the usage of
human embryonic stem cells for the purpose of
transplantation. To overcome this problem, some
researchers have isolated a population of stem cells from
human cord blood, a plentiful source with simple collection
procedures. These cells express embryo stage specific
marker, SSEA-4, and the multi-potential stem cell marker,
Oct4. Upon proper stimulation these cells can be turned into
insulin producing cells.23
Human embryonic stem cells, due to their high
proliferative capacity, have the potential to form teratomas
in the recipient.24 Moreover, depending upon the source of
these cells, they can be rejected by the host immune system. 
Immunologically competent embryonic stem
cells: Type 1 diabetes mellitus results from T cell-mediated
autoimmune destruction of pancreatic insulin-producing ß
cells. This will remain a problem even when stem cells are
transplanted from outside sources. To overcome this
problem cloning technology can be applied, where nucleus
of the patient's own somatic cell is taken and inserted into
an enucleated human egg and allowed to develop into the
blastocyst stage. The embryonic stem cells derived thus
from the inner cell mass are immunologically competent
thereby avoiding allogeneic host versus graft reactions and
the need for immunosuppressive therapy. These cells are
cultured in vitro and allowed to expand to produce the
billions of cells needed for transplantation therapy.25
Adult pancreatic stem cells - do they really exist?
Another potential source of stem cells is found in the adult
tissue. These cells are responsible for cell turnover or repair
of tissues under normal circumstances. During foetal
development, these cells can be identified by their
characteristic markers such as Pdx-1, which is specific for
beta cells. After birth and later in adult life, controversy exist
as to the presence of stem cells in the pancreas.26 Recent
research, however, has shown the presence of stem-like cells
within both the adult pancreas islets and pancreatic ducts by
identifying a separate marker called nestin, normally found
in developing neural cells. Further differentiation of the
cells, into liver or pancreatic cells, depend upon the type of
growth factor added to the medium.27
Although adult stem cells have the obvious
advantage of having fewer ethical issues involved and are
non-immmunogenic being part of one's own body, the main
disadvantage is that they are not easy to cultivate and are
much less prolific than embryonic stem cells.28
Only beta cells or all cells of the Islets: The normal
response of the body to a glycaemic load is an initial quick
release of insulin followed by a slower gradual discharge in
order to fine tune the blood glucose level. Research has
revealed that this pattern is not followed when only the beta
cells are transplanted, however, control is achieved by
transplanting all the cells of the islets. This is due to the fact
that the islet cells influence each other via gap junctions in
controlling the release of insulin from beta cells according
to the physiological needs which would not be possible by
transplanting beta cells alone.29,30
Autoimmunity: Even if we achieve in gathering
enough beta cells by any means for transplantation, the
problem of autoimmunity may still be there. One way to
avoid detection by the immune system theoretically is to
downregulate the expression of the major histocompatibility
complex antigens present over the surface of the cell. In this
regard a potential advantage of using embryonic stem cells
is that they are more amenable to genetic alteration than are
adult stem cells. In addition, it has been found that the
expression of major histocompatibility complex antigens is
inherently much less on embryonic stem cells than on adult
stem cells.31,32 Another promising area of research is
monoclonal antibodies against particular T cell involved in
the process of autoimmunity. Recent advancement in this
regard is the development of a drug Thioredoxin-4; an anti-
CD3 humanized monoclonal antibody, which is about to
enter its phase III clinical trials. It has been shown that when
administered for a course of six days, Thioredoxin-4 slowed
deterioration of beta cells as well as decreased the amount
of insulin needed from outside.33,34
Conclusion
With the rise in the incidence of diabetes mellitus
and its added burden to the society, it is imperative that a
cure be found for the disease. Research is going on in
various directions from improving the quality and delivery
of insulin to forming new beta cells. Stem cell technology
has revolutionalized this scenario and the goal of finding a
cure for diabetes seems to be within reach. In this regard,
human embryonic stem cells seem ideal for the purpose as
they fulfill the requirement of being easily available and
able to divide rapidly to large enough numbers to be used
for any practical purpose. Legal and ethical issues are still
there, causing stem cell research to turn its head towards
adult stem cells. Moreover, it may take many years to
convert this research into a clinically useful application
within reach of mankind. In the meanwhile we will have to
find new ways to monitor blood glucose and administer
insulin, maybe without the painful needle. 
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